Glenmark Pharmaceuticals Limited became the first company in India to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination (FDC) for the treatment of adult patients with type 2 diabetes, especially the ones with comorbidities. Marketed under the brand name Zita D, it contains Teneligliptin (20mg) + Dapagliflozin (5mg/10mg), and must be taken once daily under prescription to improve glycemic control and prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities.
Alok Malik, EVP & Business Head, India Formulations, Glenmark Pharmaceuticals, said, “Glenmark being a leader in the diabetes segment in India is proud to bring Zita D, a well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities.”
While Zita D is a promising treatment option in managing uncontrolled Type 2 diabetes with co-morbidities, this FDC has also proven to be effective among adult diabetic patients without comorbidities. Glenmark’s Zita D is priced at around Rs 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and Rs 15 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 10mg, per day.
